Complex role of γδ T-cell-derived cytokines and growth factors in cancer

Journal of Interferon and Cytokine Research

Volumn 32, Issue 12, 2012, Pages 563-569

  Ramstead, Andrew G ^a   Jutila, Mark A ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 9; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ZOLEDRONIC ACID;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MATURATION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; GAMMA DELTA T LYMPHOCYTE; HUMAN; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTIGEN-PRESENTING CELLS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

MUS;

EID: 84870498304     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0073     Document Type: Review

References (62)

1. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K, Suzuki K. 2009. Clinical and immunological evaluation of zoledronate- activated Vgamma9- gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37(8):956-968.
2. Alshaker HA, Matalka KZ. 2011. IFN-g, IL-17 and TGF-b involvement in shaping the tumor microenvironment: the significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int 11:33.
3. Argentati K, Re F, Serresi S, Tucci MG, Bartozzi B, Bernardini G, Provinciali M. 2003. Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma. J Invest Dermatol 120(5): 829-834. (Pubitemid 36529086)
4. Behr B, Leucht P, Longaker MT, Quarto N. 2010. Fgf-9 is required for angiogenesis and osteogenesis in long bone repair. Proc Natl Acad Sci U S A 107(26):11853-11858.
5. Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, Touraine JL, Clézardin P. 2011. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 71(13):4562-4572.
6. Bialasiewicz AA, Ma JX, Richard G. 1999. Alpha/beta- and gamma/delta TCR( + ) lymphocyte infiltration in necrotising choroidal melanomas. Br J Ophthalmol 83(9):1069-1073. (Pubitemid 29433432)
7. Bonneville M, O'Brien RL, Born WK. 2010. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10(7):467-478.
8. Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, Arnouk H, Su Y, Haines HL, Suarez-Cuervo C, Lamb LS, Jr. 2011. Preclinical evaluation of ex vivo expanded/ activated gd T cells for immunotherapy of glioblastoma multiforme. J Neurooncol 101(2):179-188.
9. Capietto AH, Martinet L, Fournié JJ. 2011. How tumors might withstand gd T-cell attack. Cell Mol Life Sci 68(14): 2433-2442.
10. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN. 2011. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 186(6): 3462-3471.
11. Castella B, Vitale C, Coscia M, Massaia M. 2011. Vg9Vd2 T cellbased immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci 68(14):2419-2432.
12. Ceccarelli S, Romano F, Angeloni A, Marchese C. 2012. Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages. Expert Opin Ther Targets 16(4):377-393.
13. Chow MT, Möller A, Smyth MJ. 2012. Inflammation and immune surveillance in cancer. Semin Cancer Biol 22(1):23-32.
14. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC. 2007. Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone- refractory prostate cancer. Cancer Res 67(15): 7450-7457. (Pubitemid 47206575)
15. Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, Sosman JA, Lam VA, Sondel PM. 1990. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med 171(5):1567-1579. (Pubitemid 20167551)
16. Gaafar A, Aljurf MD, Al-Sulaiman A, Iqniebi A, Manogaran PS, Mohamed GE, Al-Sayed A, Alzahrani H, Alsharif F, Mohareb F, Ajarim D, Tabakhi A, Al-Hussein K. 2009. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol 37(7):838-848.
17. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. 2003. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198(3):433-442. (Pubitemid 36976054)
18. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. 2001. Regulation of cutaneous malignancy by gammadelta T cells. Science 294(5542):605-609. (Pubitemid 32999559)
19. Gomes AQ, Martins DS, Silva-Santos B. 2010. Targeting gd T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 70(24): 10024-10027.
20. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. 1999. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96(12):6879-6884. (Pubitemid 29274978)
21. Halary F, Pitard V, Dlubek D, Krzysiek R, de la Salle H, Merville P, Dromer C, Emilie D, Moreau JF, Dechanet-Merville J. 2005. Shared reactivity of Vdelta2neg gamma delta T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 201(10):1567-1578. (Pubitemid 40721002)
22. Hannani D, Ma Y, Yamazaki T, Déchanet-Merville J, Kroemer G, Zitvogel L. 2012. Harnessing gd T cells in anticancer immunotherapy. Trends Immunol 33(5):199-206.
23. Hao J, Dong S, Xia S, He W, Jia H, Zhang S, Wei J, O'Brien RL, Born WK, Wu Z, Wang P, Han J, Hong Z, Zhao L, Yin Z. 2011. Regulatory role of Vg1 gd T cells in tumor immunity through IL-4 production. J Immunol 187(10):4979-4986.
24. Hao J, Wu X, Xia S, Li Z, Wen T, Zhao N, Wu Z, Wang P, Zhao L, Yin Z. 2010. Current progress in gd T-cell biology. Cell Mol Immunol 7(6):409-413.
25. He W, Hao J, Dong S, Gao Y, Tao J, Chi H, Flavell R, O'Brien RL, Born WK, Craft J, Han J, Wang P, Zhao L, Wu J, Yin Z. 2010. Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol 185(1):126-133.
26. Holtmeier W, Kabelitz D. 2005. Gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 86:151-183.
27. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, Kwon ED. 2008. Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. J Immunol 180(5): 3578-3584.
28. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, Havran WL. 2002. A role for skin gammadelta T cells in wound repair. Science 296(5568):747-749. (Pubitemid 34442005)
29. Kalyan S, Wesch D, Kabelitz D. 2011. Aminobisphosphonates and toll-like receptor ligands: recruiting Vg9Vd2 T cells for the treatment of hematologic malignancy. Curr Med Chem 18(34):5206-5216.
30. Ke Y, Kapp LM, Kapp JA. 2003. Inhibition of tumor rejection by gammadelta T cells and IL-10. Cell Immunol 221(2):107-114. (Pubitemid 36549085)
31. Kühl AA, Pawlowski NN, Grollich K, Blessenohl M, Westermann J, Zeitz M, Loddenkemper C, Hoffmann JC. 2009. Human peripheral gammadelta T cells possess regulatory potential. Immunology 128(4):580-588.
32. Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, Becker J, Schmidt-Wolf IG, Einsele H, Wilhelm M. 2012. Tumor-promoting versus tumor- antagonizing roles of gd T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 35(2): 205-213.
33. Lejeune FJ, Liénard D, Matter M, Rüegg C. 2006. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6.
34. Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, Nakamura H, Yamanishi H, Terada N, Okamura H. 2010. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother 33(3):287-296.
35. Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, Nakamura H, Yamanishi H, Terada N, Okamura H. 2010. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother 33(3):287-296.
36. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B. 2011. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407(2):348-354.
37. Lu Y, Yang W, Qin C, Zhang L, Deng J, Liu S, Qin Z. 2009. Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol 183(10):6413-6421.
38. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L. 2011. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208(3):491-503.
39. Martinet L, Fleury-Cappellesso S, Gadelorge M, Dietrich G, Bourin P, Fournié JJ, Poupot R. 2009. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells. Eur J Immunol 39(3):752-762.
40. Moser B, Eberl M. 2011. gd T-APCs: a novel tool for immunotherapy? Cell Mol Life Sci 68(14):2443-2452.
41. Ness-Schwickerath KJ, Morita CT. 2011. Regulation and function of IL-17A- and IL-22- producing gd T cells. Cell Mol Life Sci 68(14):2371-2390.
42. Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, Tsao MS, Chiao PJ. 2007. Keratinocyte growth factor/fibroblast growth factor- 7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem 282(9): 6001-6011. (Pubitemid 47100871)
43. Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ. 2012. Role of gd T cells in a- galactosylceramide-mediated immunity. J Immunol 188(8):3928-3939.
44. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. 2007. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique tolllike receptor signaling pathway. Immunity 27(2):334-348. (Pubitemid 47284914)
45. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, Steinle A, Ghia P, Stella S, Caligaris-Cappio F, Zocchi MR. 2004. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 64(24):9172-9179. (Pubitemid 39665533)
46. Provinciali M, Re F, Tucci MG, Ricotti F, Lattanzio F. 2010. Persistent ex vivo low number and functional in vitro recovery of circulating gammadelta T cells after removal of a cutaneous primary melanoma. Scand J Immunol 72(2):142-149.
47. Puan KJ, Low JS, Tan TW, Wee JT, Tan EH, Fong KW, Chua ET, Jin C, Giner JL, Morita CT, Goh CH, Hui KM. 2009. Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma. Cancer Immunol Immunother 58(7):1095-1107.
48. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. 2005. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 175(4):2144-2151. (Pubitemid 41113819)
49. Riond J, Rodriguez S, Nicolau ML, al Saati T, Gairin JE. 2009. In vivo major histocompatibility complex class I (MHCI) expression on MHCI low tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun 9:10.
50. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. 2011. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17(7):347-362.
51. Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M. 2008. Immune response of human propagated gammadelta- T-cells to neuroblastoma recommend the Vdelta1 + subset for gammadelta-T-cell-based immunotherapy. J Immunother 31(9):896-905.
52. Seo N, Tokura Y, Furukawa F, Takigawa M. 1998. Downregulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions. J Immunol 161(8):4138-4145. (Pubitemid 28468994)
53. Seo N, Tokura Y, Takigawa M, Egawa K. 1999. Depletion of IL- 10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 163(1):242-249. (Pubitemid 29295847)
54. Sugaya M, Nakamura K, Tamaki K. 1999. Interleukins 18 and 12 synergistically upregulate interferon-gamma production by murine dendritic epidermal T cells. J Invest Dermatol 113(3): 350-354. (Pubitemid 29449073)
55. Takeuchi A, Dejima T, Yamada H, Shibata K, Nakamura R, Eto M, Nakatani T, Naito S, Yoshikai Y. 2011. IL-17 production by gd T cells is important for the anti-tumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol 41(1):246-251.
56. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH. 1987. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47(10): 2563-2570. (Pubitemid 17083141)
57. Vakkila J, Lotze MT. 2004. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4(8):641-648. (Pubitemid 39025049)
58. Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, Kitamura H,Nishimura T. 2010. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol 40(7): 1927-1937.
59. Welte T, Lamb J, Anderson JF, Born WK, O'Brien RL, Wang T. 2008. Role of two distinct gammadelta T cell subsets during West Nile virus infection. FEMS Immunol Med Microbiol 53(2):275-283. (Pubitemid 351832195)
60. Wesch D, Glatzel A, Kabelitz D. 2001. Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype. Cell Immunol 212(2):110-117. (Pubitemid 34044542)
61. Workalemahu G, Foerster M, Kroegel C. 2004. Expression and synthesis of fibroblast growth factor-9 in human gammadelta T-lymphocytes. Response to isopentenyl pyrophosphate and TGF-beta1/IL-15. J Leukoc Biol 75(4):657-663. (Pubitemid 38405657)
62. Yoshida Y, Nakajima J, Wada H, Kakimi K. 2011. gd T-cell immunotherapy for lung cancer. Surg Today 41(5):606-611.